Feder Julie B 4
4 · Aura Biosciences, Inc. · Filed Oct 21, 2024
Insider Transaction Report
Form 4
Feder Julie B
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-10-18−2,631→ 32,359 totalExercise: $4.25Exp: 2030-03-16→ Common Stock (2,631 underlying) - Exercise/Conversion
Common Stock
2024-10-18$2.74/sh+17,500$47,950→ 151,776 total - Sale
Common Stock
2024-10-18$12.03/sh−25,131$302,361→ 134,276 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-18−17,500→ 68,257 totalExercise: $2.74Exp: 2028-10-03→ Common Stock (17,500 underlying) - Exercise/Conversion
Common Stock
2024-10-18$4.25/sh+2,631$11,182→ 154,407 total - Exercise/Conversion
Common Stock
2024-10-18$5.48/sh+5,000$27,400→ 159,407 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-18−5,000→ 120,547 totalExercise: $5.48Exp: 2031-06-28→ Common Stock (5,000 underlying)
Footnotes (4)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option is fully vested.
- [F4]The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021.